Assessment of the Clinical Utility of Glypican 3 as a Serum Marker for the Diagnosis of Hepatocellular Carcinoma

Technology in Cancer Research and Treatment

Volumn 15, Issue 6, 2016, Pages 780-786

  Jia, Xiaobo ^a,b   Gao, Yingtang ^c   Zhai, Daokuan ^c   Liu, Jiao ^a   Cai, Junjun ^a   Wang, Yajie ^a   Jing, Li ^c   Du, Zhi ^c  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b XUZHOU MEDICAL UNIVERSITY   (China)

^c THIRD CENTRAL HOSPITAL OF TIANJIN   (China)

Author keywords

ELISA; glypican 3; hepatocellular carcinoma; serum; fetoprotein

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; GLYPICAN 3; GLYPICAN; GPC3 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; ATYPICAL DUCTAL HYPERPLASIA; CHRONIC HEPATITIS B; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC VALUE; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; BLOOD; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; METABOLISM; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ALPHA-FETOPROTEINS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYPICANS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84994803148     PISSN: 15330346     EISSN: 15330338     Source Type: Journal    
DOI: 10.1177/1533034615605248     Document Type: Article

References (30)

1. Spangenberg HC, Thimme R, Blum HE. Serum markers of hepatocellular carcinoma. Seminars in liver disease. 2006;26(4):385–390.
2. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–1022.
3. Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest. 2001;108(4):497–501.
4. Yamauchi N, Watanabe A, Hishinuma M. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Modern Pathol. 2005;18(12):1591–1598.
5. Nakatsura T, Yoshitake Y, Senju S. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophysical Res Commun. 2003;306(1):16–25.
6. Chen IP, Ariizumi S, Nakano M. Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy. J Gastroenterol. 2014;49(1):117–125.
7. Yan B, Wei JJ, Qian YM. Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma. Ann Diagn Pathol. 2011;15(3):162–169.
8. Capurro M, Wanless IR, Sherman M. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003;125(1):89–97.
9. Qiao S S, Cui Z Q, Gong L. Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma. Hepatogastroenterology. 2010;58(110-111):1718–1724.
10. Lee HJ, Yeon JE, Suh SJ. Clinical utility of glypican-3 in hepatocellular carcinoma. Int J Integr Biol. 2014;10(1):41–47.
11. Zhang Q, Xiao Q, Lin Z. Development of a competitive radioimmunoassay for glypican-3 and the clinical application in diagnosis of hepatocellular carcinoma. Clin Biochem. 2010;43(12):1003–1008.
12. Abdelgawad IA, Mossallam GI, Radwan NH. Can Glypican3 be diagnostic for early hepatocellular carcinoma among Egyptian patients? Asian Pac J Cancer Prev. 2013;14(12):7345–7349.
13. Yasuda E, Kumada T, Toyoda H. Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Glypican-3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma. Hepatol Res. 2010;40(5):477–485.
14. Özkan H, Erdal H, Koçak E. Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma. J Clin Lab Analysis. 2011;25(5):350–353.
15. Pepe MS, Etzioni R, Feng Z. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001;93(14):1054–1061.
16. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–1236.
17. Nakatsura T, Yoshitake Y, Senju S. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun. 2003;306(1):16–25.
18. Liu H, Li P, Zhai Y. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol. 2010;16(35):4410.
19. Yao M, Yao DF, Bian YZ. Values of circulating GPC-3 mRNA and alpha-fetoprotein in detecting patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2013;12(2):171–179.
20. Yu JP, Ma Q, Zhang B. Clinical application of specific antibody against glypican-3 for hepatocellular carcinoma diagnosis. Sci China Life Sci. 2013;56(3):234–239.
21. Beale G, Chattopadhyay D, Gray J. AFP, PIVKAII, GP3, SCCA-1 and follistatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer. 2008;8(1):200.
22. Di Tommaso L, Destro A, Seok JY. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol. 2009;50(4):746–754.
23. Wang FH, Yip YC, Zhang M. Diagnostic utility of glypican-3 for hepatocellular carcinoma on liver needle biopsy. J Clin Pathol. 2010;63(7):599–603.
24. Yan B, Wei JJ, Qian YM. Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma. Ann Diagn Pathol. 2011;15(3):162–169.
25. Saad Y, El-Serafy M, Eldin M S. New genetic markers for diagnosis of hepatitis C related hepatocellular carcinoma in Egyptian patients. J Gastrointestin Liver Dis. 2013;22(4):419–425.
26. Tangkijvanich P, Chanmee T, Komtong S. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. J Gastroenterol Hepatol. 2010;25(1):129–137.
27. Chen M, Li G, Yan J. Reevaluation of glypican-3 as a serological marker for hepatocellular carcinoma. Clin Chim Acta. 2013;423:105–111.
28. Yamauchi N, Watanabe A, Hishinuma M. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol. 2005;18(12):1591–1598.
29. Baumhoer D, Tornillo L, Stadlmann S. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol. 2008;129(6):899–906.
30. Abdul-Al HM, Makhlouf HR, Wang G, Goodman ZD. Glypican-3 expression in benign liver tissue with active hepatitis C: implications for the diagnosis of hepa-tocellular carcinoma. Hum Pathol. 2008;39(2):209–212.